Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Crude Inventory Rose 2 Million Barrels Last Week - EIA
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
Zymeworks to acquire Theravance Biopharma for $17 per share
June 29, 2026 6:01 AM EDTZymeworks Inc. has agreed to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH) for $17.00 per share in cash, representing an equity value of approximately $929 million, according to a press release issued June 29, 2026.
Theravance Biopharma shareholders will also receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture, or other... More
Zymeworks to buy Theravance Biopharma for $17 per share
June 29, 2026 6:00 AM EDTZymeworks Inc. (NASDAQ: ZYME) announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH) at $17.00 per share in cash, representing a total transaction value of approximately $929 million, subject to customary adjustments.
The acquisition adds YUPELRI (revefenacin), a nebulized long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease,... More
